We are analyzing https://link.springer.com/article/10.1245/s10434-011-2086-4.

Title:
Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer | Annals of Surgical Oncology
Description:
Pathologic response to preoperative therapy is increasingly recognized as an important prognostic factor in solid tumors. The impact of pathologic response on survival in pancreatic adenocarcinoma is not well established. Data on 135 consecutive patients treated with chemoradiation followed by pancreatectomy for adenocarcinoma of the pancreatic head and/or body between July 1987 and May 2009 were reviewed. Histopathologic examination was performed in 107 patients to determine pathologic response, defined as minor (<50% fibrosis relative to residual neoplastic cells), partial (50–94% fibrosis), or major (95–100% fibrosis). Minor, partial, and major pathologic response rates were 17% (n = 18), 64% (n = 68), and 19% (n = 21), including a 7% (n = 8) complete pathologic response rate. Pathologic response correlated with R0 resection (P = 0.019), negative lymph nodes (P = 0.006), and smaller tumor size (P = 0.001). Median survival rates by pathologic response were as follows: 17 months [95% confidence interval (CI), 0–36 months] for minor response, 20 months (95% CI, 17–23 months) for partial response, and 66 months (95% CI, 8–124 months) for major response (minor versus partial response, P = not significant; partial versus major response, P < 0.001). On multivariate analysis, major pathologic response was the only factor significantly associated with improved survival (P = 0.025; hazard ratio, 2.26). Major pathologic response to preoperative therapy occurs in a minority of patients with pancreatic adenocarcinoma and is independently associated with prolonged survival.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Non-Profit & Charity
Telecommunications
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,182 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

article, pancreatic, response, cancer, pubmed, google, scholar, pathologic, adenocarcinoma, oncol, cas, preoperative, surg, resectable, patients, ann, chemoradiotherapy, survival, chemoradiation, pancreas, hoffman, major, months, chemotherapy, clin, privacy, cookies, content, oncology, therapy, chun, partial, borderline, outcome, neoadjuvant, usa, analysis, data, publish, search, surgical, significance, cooper, head, minor, complete, resection, access, clinical, gemcitabine,

Topics {✒️}

month download article/chapter negative lymph nodes de campos-lobato lf contemporary single-institution experience preoperative gemcitabine-based chemoradiation advanced pancreatic cancer doxorubicin-based neoadjuvant chemotherapy full article pdf article chun resected pancreatic cancer gemcitabine-based chemoradiation privacy choices/manage cookies related subjects smaller tumor size wayne state university andre konski md pathologic complete response resectable pancreatic adenocarcinoma combined modality treatment expert consensus statement breast cancer patients determine pathologic response pathologic response correlated major pathologic response randomised controlled trial barbara burtness md igor astsaturov md serum ca19-9 response article annals pancreatic cancer european economic area residual neoplastic cells defining venous involvement varadhachary gr localized gastric carcinoma surgical margin status randomized controlled trial evans db conditions privacy policy hepatobiliary pancreat surg surgical oncology aims important prognostic factor preoperative endorectal ultrasonography paclitaxel-based chemoradiotherapy preoperative therapy occurs median survival rates ann surg oncol accepting optional cookies check access instant access

Questions {❓}

Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer
         description:Pathologic response to preoperative therapy is increasingly recognized as an important prognostic factor in solid tumors. The impact of pathologic response on survival in pancreatic adenocarcinoma is not well established. Data on 135 consecutive patients treated with chemoradiation followed by pancreatectomy for adenocarcinoma of the pancreatic head and/or body between July 1987 and May 2009 were reviewed. Histopathologic examination was performed in 107 patients to determine pathologic response, defined as minor (<50% fibrosis relative to residual neoplastic cells), partial (50–94% fibrosis), or major (95–100% fibrosis). Minor, partial, and major pathologic response rates were 17% (n = 18), 64% (n = 68), and 19% (n = 21), including a 7% (n = 8) complete pathologic response rate. Pathologic response correlated with R0 resection (P = 0.019), negative lymph nodes (P = 0.006), and smaller tumor size (P = 0.001). Median survival rates by pathologic response were as follows: 17 months [95% confidence interval (CI), 0–36 months] for minor response, 20 months (95% CI, 17–23 months) for partial response, and 66 months (95% CI, 8–124 months) for major response (minor versus partial response, P = not significant; partial versus major response, P < 0.001). On multivariate analysis, major pathologic response was the only factor significantly associated with improved survival (P = 0.025; hazard ratio, 2.26). Major pathologic response to preoperative therapy occurs in a minority of patients with pancreatic adenocarcinoma and is independently associated with prolonged survival.
         datePublished:2011-09-27T00:00:00Z
         dateModified:2011-09-27T00:00:00Z
         pageStart:3601
         pageEnd:3607
         sameAs:https://doi.org/10.1245/s10434-011-2086-4
         keywords:
            Pancreatic Cancer
            Gemcitabine
            Pancreatic Adenocarcinoma
            Pathologic Response
            Negative Lymph Node
            Surgical Oncology
            Oncology
            Surgery
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1245%2Fs10434-011-2086-4/MediaObjects/10434_2011_2086_Fig1_HTML.gif
         isPartOf:
            name:Annals of Surgical Oncology
            issn:
               1534-4681
               1068-9265
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yun Shin Chun
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Harry S. Cooper
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Department of Pathology, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Steven J. Cohen
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andre Konski
               affiliation:
                     name:Wayne State University
                     address:
                        name:Department of Radiation Oncology, Wayne State University, Detroit, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Barbara Burtness
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Crystal S. Denlinger
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Igor Astsaturov
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael J. Hall
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John P. Hoffman
               affiliation:
                     name:Fox Chase Cancer Center
                     address:
                        name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer
      description:Pathologic response to preoperative therapy is increasingly recognized as an important prognostic factor in solid tumors. The impact of pathologic response on survival in pancreatic adenocarcinoma is not well established. Data on 135 consecutive patients treated with chemoradiation followed by pancreatectomy for adenocarcinoma of the pancreatic head and/or body between July 1987 and May 2009 were reviewed. Histopathologic examination was performed in 107 patients to determine pathologic response, defined as minor (<50% fibrosis relative to residual neoplastic cells), partial (50–94% fibrosis), or major (95–100% fibrosis). Minor, partial, and major pathologic response rates were 17% (n = 18), 64% (n = 68), and 19% (n = 21), including a 7% (n = 8) complete pathologic response rate. Pathologic response correlated with R0 resection (P = 0.019), negative lymph nodes (P = 0.006), and smaller tumor size (P = 0.001). Median survival rates by pathologic response were as follows: 17 months [95% confidence interval (CI), 0–36 months] for minor response, 20 months (95% CI, 17–23 months) for partial response, and 66 months (95% CI, 8–124 months) for major response (minor versus partial response, P = not significant; partial versus major response, P < 0.001). On multivariate analysis, major pathologic response was the only factor significantly associated with improved survival (P = 0.025; hazard ratio, 2.26). Major pathologic response to preoperative therapy occurs in a minority of patients with pancreatic adenocarcinoma and is independently associated with prolonged survival.
      datePublished:2011-09-27T00:00:00Z
      dateModified:2011-09-27T00:00:00Z
      pageStart:3601
      pageEnd:3607
      sameAs:https://doi.org/10.1245/s10434-011-2086-4
      keywords:
         Pancreatic Cancer
         Gemcitabine
         Pancreatic Adenocarcinoma
         Pathologic Response
         Negative Lymph Node
         Surgical Oncology
         Oncology
         Surgery
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1245%2Fs10434-011-2086-4/MediaObjects/10434_2011_2086_Fig1_HTML.gif
      isPartOf:
         name:Annals of Surgical Oncology
         issn:
            1534-4681
            1068-9265
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yun Shin Chun
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Harry S. Cooper
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Department of Pathology, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Steven J. Cohen
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andre Konski
            affiliation:
                  name:Wayne State University
                  address:
                     name:Department of Radiation Oncology, Wayne State University, Detroit, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Barbara Burtness
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Crystal S. Denlinger
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Igor Astsaturov
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael J. Hall
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John P. Hoffman
            affiliation:
                  name:Fox Chase Cancer Center
                  address:
                     name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Annals of Surgical Oncology
      issn:
         1534-4681
         1068-9265
      volumeNumber:18
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Fox Chase Cancer Center
      address:
         name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Department of Pathology, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:Wayne State University
      address:
         name:Department of Radiation Oncology, Wayne State University, Detroit, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center
      address:
         name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yun Shin Chun
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Harry S. Cooper
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Department of Pathology, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Steven J. Cohen
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Andre Konski
      affiliation:
            name:Wayne State University
            address:
               name:Department of Radiation Oncology, Wayne State University, Detroit, USA
               type:PostalAddress
            type:Organization
      name:Barbara Burtness
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Crystal S. Denlinger
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Igor Astsaturov
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Michael J. Hall
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:John P. Hoffman
      affiliation:
            name:Fox Chase Cancer Center
            address:
               name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
      name:Department of Pathology, Fox Chase Cancer Center, Philadelphia, USA
      name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
      name:Department of Radiation Oncology, Wayne State University, Detroit, USA
      name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
      name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
      name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
      name:Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
      name:Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(112)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.63s.

LINK . SPRINGER . COM {}